Arvinas Announces New Pfizer Collab Actions To Create Value
Arvinas and Pfizer will out-license commercialization rights for vepdegestrant, an oral PROTAC estrogen receptor degrader under FDA review for...
Arvinas and Pfizer will out-license commercialization rights for vepdegestrant, an oral PROTAC estrogen receptor degrader under FDA review for...
The European Commission has granted marketing authorization for Biogen’s Zurzuvae (zuranolone) to treat postpartum depression in adults, establishing the...
Rezolute reported fiscal Q4 and full-year 2025 results alongside two pivotal updates for its lead asset, Ersodetug: completion of...
PCI Biotech has halted development of its photochemical lysis platform intended to boost adeno-associated virus manufacturing yields. It is...
Rakovina Therapeutics reported a Q2 2025 net loss of C$2.92 million on operating expense cash burn of approximately C$2.65...
Rezolute completed enrollment in sunRIZE, its registrational Phase 3 study of ersodetug in congenital hyperinsulinism (HI), with topline data...
Roche has signed a definitive agreement to acquire 89bio for $14.50 per share in cash plus a non-tradeable CVR...
Pharmagri Capital Partners has outlined an aggressive plan to build a sovereign, vertically integrated “seed-to-prescription” platform targeting roughly $10...
Spyglass Pharma has named Anand Sundaram as vice president, head of commercial, as the company advances its intraocular lens–mounted,...
Harvard Bioscience has expanded its distribution agreement with Fisher Scientific to include the United States, adding pumps, spectrophotometers, and...